Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619000192189
Ethics application status
Approved
Date submitted
18/01/2019
Date registered
11/02/2019
Date last updated
17/12/2020
Date data sharing statement initially provided
11/02/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Cimetidine for Reducing Oxaliplatin Neurotoxicity (CITRON)
Query!
Scientific title
Reducing Oxaliplatin Neurotoxicity: A Phase IB Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer Patients
Query!
Secondary ID [1]
296688
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Colorectal cancer
310880
0
Query!
Gastrointestinal cancer
310881
0
Query!
Condition category
Condition code
Cancer
309557
309557
0
0
Query!
Bladder
Query!
Cancer
310082
310082
0
0
Query!
Bowel - Anal
Query!
Cancer
310083
310083
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Cancer
310084
310084
0
0
Query!
Bowel - Small bowel (duodenum and ileum)
Query!
Cancer
310085
310085
0
0
Query!
Oesophageal (gullet)
Query!
Cancer
310086
310086
0
0
Query!
Pancreatic
Query!
Cancer
310093
310093
0
0
Query!
Liver
Query!
Cancer
310094
310094
0
0
Query!
Stomach
Query!
Cancer
310095
310095
0
0
Query!
Biliary tree (gall bladder and bile duct)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Subjects will be randomly allocated to blinded treatment with cimetidine during cycle one of oxaliplatin treatment then crossover to placebo treatment in cycle two, or will receive the same blinded treatments in the opposite sequence. Cimetidine or placebo capsules will be given as a single oral dose 0.5 hours prior to commencement of the oxaliplatin infusion.
In the dose-escalation phase of the trial, the dose of cimetidine will be increased sequentially in cohorts of three patients using a traditional 3+3+3 rule-based oncology phase I clinical trial design. The dose escalation phase of the trial will explore cimetidine treatment given concurrently with oxaliplatin at six dose-levels (200, 400, 800, 1200, 1600 and 2000 mg).
Following treatment of the first cohort of three patients at a given dose-level, three main possibilities exist: 1) if all three patients have DLT, then that dose-level will be declared the MTD and the next cohort of three patients will be treated at the next lowest dose-level; 2) if none of three patients have DLT, then the next cohort of three patients will be treated with the next highest dose level, and; 3) if one or two of three patients had DLT, then the next cohort of three patients will be treated at the same dose-level to expand that dose level. Dose escalation may stop when one or more of the following has occurred: 1) the maximally tolerated dose of cimetidine is reached; 2) cimetidine was found to significantly alter the pharmacokinetics of oxaliplatin, or; 3) the recommended dose for cohort expansion of cimetidine has been reached.
After identifying a cimetidine dose recommended for cohort expansion, 30 patients will be recruited to receive a fixed dose of cimetidine using the crossover design to generate clinical proof-of-concept in the cohort expansion phase of the trial.
Oxaliplatin chemotherapy (dose of either (= or > 100 mg/m2 ) will be given as per institutional protocols for standard care as an intravenous infusion over 2 hours using an infusion pump to achieve a constant rate of infusion during the period of oxaliplatin administration. Frequency of administration will be dependent on the chemo regimen prescribed the doctor which may be administration of the chemotherapy on Day 1 of a 2 or 3 weekly cycle. Similarly, a washout period of two to three weeks (depending on the chemo regimen) will occur between the first and second treatments.
Intervention adherence or fidelity is not NA to the chemotherapy given as it will be as per standard care. The cimetidine/placebo will be given to the patient to take orally by a research nurse 1/2 hr before chemotherapy begins.
Query!
Intervention code [1]
313204
0
Treatment: Drugs
Query!
Comparator / control treatment
Subjects will be randomly allocated to blinded treatment with cimetidine during cycle one of oxaliplatin treatment then crossover to placebo treatment in cycle two, or will receive the same blinded treatments in the opposite sequence. Cimetidine or placebo capsules will be given as a single oral dose 0.5 hours prior to commencement of the oxaliplatin infusion.
The comparator study treatment will be matching placebo capsules containing no cimetidine. Placebo capsules will be given as a single oral dose 0.5 hours prior to the commencement of the oxaliplatin infusion.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
318507
0
Plasma pharmacokinetics of intact oxaliplatin defined by plasma concentration at steady-state (Css) and area under the plasma concentration-versus-time curve (AUC) of intact oxaliplatin
Query!
Assessment method [1]
318507
0
Query!
Timepoint [1]
318507
0
Single plasma sample will be collected and processed at the end of infusion on Day 1 of Cycles 1 and 2 for the main study.
For the optional sub-study, 16 plasma samples will be collected at pre-infusion, at 20, 40, 60 and 90 minutes after the start of the oxaliplatin infusion, at the end of the infusion and 5, 10, 20, 30, 60, 120, 180, 300 minutes, 24 and 72 hours, thereafter.
Query!
Secondary outcome [1]
365186
0
Motor nerve hyperexcitability as assessed by needle electromyography undertaken on day 3 (± one day) of cycle one and cycle two by a neurophysiologist
Query!
Assessment method [1]
365186
0
Query!
Timepoint [1]
365186
0
EMG will be undertaken on day 3 (± one day) of cycle one and cycle two.
Query!
Secondary outcome [2]
366560
0
Acute neurotoxicity symptoms after treatment with oxaliplatin, as compared to placebo assessed by study-specific questionnaire
Query!
Assessment method [2]
366560
0
Query!
Timepoint [2]
366560
0
At the end of cycle one and again at the end of cycle two.
Query!
Secondary outcome [3]
366561
0
Patient preference for cimetidine or placebo for reducing acute neurotoxicity symptoms from oxaliplatin assessed by study-specific questionnaire
Query!
Assessment method [3]
366561
0
Query!
Timepoint [3]
366561
0
At the end of cycle two.
Query!
Secondary outcome [4]
366562
0
To determine the safety of cimetidine given concurrently with oxaliplatin, adverse events will be recorded at the end of cycle one and cycle two based on medical history, vital signs measurement, physical examination findings and routine clinical laboratory assessments. Investigators will grade adverse events by CTCAE v4.0 and assign their causal relationships to the blinded study treatment. Adverse events causally related to study treatment and not expected from oxaliplatin-based chemotherapy alone will be considered in the evaluation of dose-limiting toxicities and for dose escalation decisions in the dose escalation phase of the trial
Query!
Assessment method [4]
366562
0
Query!
Timepoint [4]
366562
0
At the end of cycle one and cycle two
Query!
Eligibility
Key inclusion criteria
• Histologically proven advanced-stage gastrointestinal cancer
• Scheduled to undergo standard palliative-intent oxaliplatin-based chemotherapy
• Age>18 years
• Written informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• Early- or locally advanced-stage gastrointestinal cancer for curative-intent oxaliplatin-based therapy in the adjuvant, neoadjuvant, chemoradiation or other settings
• Prior exposure to oxaliplatin or other neurotoxic chemotherapies including by not limited cisplatin, vincristine, vinorelbine, docetaxel or paclitaxel.
• Pregnant or nursing women
• Any concomitant medications recommended to avoid with cimetidine or oxaliplatin
• Creatinine clearance less than or equal to 50ml/min
• Total bilirubin greater than 1.5*ULN
• AST or ALT greater than 3.0*ULN or greater than 5.0*ULN if due to liver metastases
• Pre-existing peripheral neuropathy greater than Grade 1
• Contraindications to EMG
• Contraindications to repeated pharmacokinetic blood sampling
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
17/06/2019
Query!
Actual
17/07/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
6
Query!
Final
Query!
Recruitment outside Australia
Country [1]
21164
0
New Zealand
Query!
State/province [1]
21164
0
Query!
Funding & Sponsors
Funding source category [1]
301265
0
Government body
Query!
Name [1]
301265
0
Health Research council
Query!
Address [1]
301265
0
PO Box 5541, Wellesley Street, Auckland 1141
Query!
Country [1]
301265
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
University of Auckland
Query!
Address
85 Park Road, Grafton, Auckland, 1023
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
300906
0
None
Query!
Name [1]
300906
0
Query!
Address [1]
300906
0
Query!
Country [1]
300906
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
302009
0
Northern B Health and Disability Ethics Committee
Query!
Ethics committee address [1]
302009
0
Ministry of Health
133 Molesworth Street
PO Box 5013
Wellington
6011
Query!
Ethics committee country [1]
302009
0
New Zealand
Query!
Date submitted for ethics approval [1]
302009
0
Query!
Approval date [1]
302009
0
21/09/2018
Query!
Ethics approval number [1]
302009
0
Query!
Summary
Brief summary
A randomized, double-blind, placebo-controlled, cross-over, phase IB clinical trial. In combination with oxaliplatin, patients will be randomized to receive either a Cimetidine capsule(s) (200, 400 or 800 mg) (active study treatment) 30 minutes prior to the oxaliplatin infusion at Cycle 1 of the chemotherapy or a matching blank capsule(s) (placebo study treatment). On the second treatment cycle (Cycle 2), the patient will cross-over to the other
study treatment (active or placebo) that they did not receive in the first treatment cycle.
Endpoints to be measured after cycle 1 and 2 for comparison within each subject will include: 1) oxaliplatin pharmacokinetics; 2) EMG motor nerve hyperexcitability score; 3) adverse events attributable to study treatment; 4) tolerability of study treatment; 5) presence or absence of acute neurotoxicity symptoms, and 6) which study
treatment was preferred by patients for reducing neurotoxicity. The study will consist of a dose-escalation phase to be followed by a cohort-expansion phase. In the dose
escalation phase, the dose of cimetidine will be escalated using a traditional 3+3+3 rule based design in sequential cohorts of three or more patients. After completion of the dose-escalation phase, a cohort-expansion phase will recruit 30 patients for the evaluation of treatment with the recommended fixed dose of cimetidine.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
88838
0
Prof Mark McKeage
Query!
Address
88838
0
University of Auckland, Faculty of Medical and Health Sciences
85 Park Road, Grafton, Auckland 1023
Query!
Country
88838
0
New Zealand
Query!
Phone
88838
0
+64 09 9237322
Query!
Fax
88838
0
Query!
Email
88838
0
[email protected]
Query!
Contact person for public queries
Name
88839
0
Miss Prashannata Khwaounjoo
Query!
Address
88839
0
University of Auckland, Faculty of Medical and Health Sciences
85 Park Road, Grafton, Auckland 1023
Query!
Country
88839
0
New Zealand
Query!
Phone
88839
0
+64 09 923 1594
Query!
Fax
88839
0
Query!
Email
88839
0
[email protected]
Query!
Contact person for scientific queries
Name
88840
0
Prof Mark McKeage
Query!
Address
88840
0
University of Auckland, Faculty of Medical and Health Sciences
85 Park Road, Grafton, Auckland 1023
Query!
Country
88840
0
New Zealand
Query!
Phone
88840
0
+64 09 923 1594
Query!
Fax
88840
0
Query!
Email
88840
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF